InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
3
T+90 hit rate
56%
T+90 mean return
+0.4%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Guyer Charles Greg, Directeur Exécutif. Insider active across 1 company, notably Biomarin Pharmaceutical INC. In total, 17 reports have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €1.5m. Activity tracked since 30 April 2021. The latest transaction was filed on 14 March 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations17 total
20,127 shares@ US$69.4440.6% of flowCommon StockSEC:0001048477-25-000031:0
7,034 shares@ US$71.27614.7% of flowCommon StockSEC:0001048477-25-000025:0
4,287 shares@ US$71.169.3% of flowCommon StockSEC:0001048477-25-000021:0
11,040 shares0Common StockSEC:0001048477-25-000017:0
55 shares@ US$56.0070.1% of flowCommon StockSEC:0001048477-24-000154:0
245 shares@ US$68.6460.5% of flowCommon StockSEC:0001048477-24-000077:0
10,550 shares0Common StockSEC:0001048477-24-000046:0
20,840 shares0Common StockSEC:0001048477-24-000024:0
133 shares@ US$69.2330.3% of flowCommon StockSEC:0001048477-23-000051:0
5,360 shares@ US$93.30414.4% of flowCommon StockSEC:0001048477-23-000035:0
239 shares@ US$66.880.5% of flowCommon StockSEC:0001209191-23-027934:0
8,900 shares0Common StockSEC:0001567619-23-005299:0
6,205 shares@ US$96.5618.5% of flowCommon StockSEC:0001567619-22-015499:0
243 shares@ US$62.4070.0001% mcap38.8% of flowCommon StockSEC:0001567619-22-009719:0
11,040 shares0Common StockSEC:0001567619-22-007183:0
221 shares@ US$62.4070.0001% mcap30.6% of flowCommon StockSEC:0001567619-21-009154:0
221 shares@ US$62.40730.6% of flowCommon StockSEC:0001567619-21-009154
17 of 17 declarations
About Guyer Charles Greg
Charles Greg Guyer is the Executive Vice President and CTO at Biomarin Pharmaceutical Inc. He is responsible for the technical direction of the company, overseeing innovation and the development of new products. Guyer is recognized for his expertise in the pharmaceutical field and his commitment to research and development.
